Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
Ligand to Report Third Quarter Financial Results on November 9, 2021
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Ligand Reports Second Quarter 2021 Financial Results
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Ligand to Report Second Quarter Financial Results on July 29, 2021
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
Ligand Reports First Quarter 2021 Financial Results
Ligand to Report First Quarter Financial Results on May 3, 2021
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
